Cas:9001-12-1 Collagenase manufacturer & supplier

Chemical Name:Collagenase

CAS.NO:9001-12-1

Synonyms:EINECS 232-582-9;MFCD00130830;D-Arginine, 1-[[[4-[(E)-2-phenyldiazenyl]phenyl]methoxy]carbonyl]-L-prolyl-L-leucylglycyl-L-prolyl-, hydrate (1:2);1-[({4-[(E)-Phenyldiazenyl]benzyl}oxy)carbonyl]-L-prolyl-L-leucylglycyl-L-prolyl-D-arginine dihydrate;Collagenase

Molecular Formula:C₃₈H₅₆N₁₀O₁₀

Molecular Weight:812.912

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:812.418091

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like EINECS 232-582-9 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Collagenase physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00130830 Use and application,1-[({4-[(E)-Phenyldiazenyl]benzyl}oxy)carbonyl]-L-prolyl-L-leucylglycyl-L-prolyl-D-arginine dihydrate technical grade,usp/ep/jp grade.

Related News: Roche too has been riding high on the stock exchange this week, as investors still hope its more extensive Alzheimer’s profile could come good. Collagenase manufacturer Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. Collagenase supplier Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. Collagenase vendor Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. Collagenase factory In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired.